It won't be easy to compare the phase II trail results from Genfit and Intercept's competing NASH drugs, but understanding the differences in their respective clinical trials should help.
Since the end of September, Hemispherx sold almost 25 million shares of company stock, equivalent to the amount of stock sold in the first nine months of 2014.
Ocular hasn't conducted clinical trials that would demonstrate that OTX-DP is any better than eye drops in reducing swelling and pain in the eye.
CTI Biopharma's experimental drug pacritinib significantly reduced the spleen size in patients with myelofibrosis compared to patients treated with best alternative care.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
AbbVie announced it is buying cancer drug-maker Pharmacyclics for $21 billion.
The $21 billion price tag for Pharmacylics only earns AbbVie rights to 50% of the blood cancer drug Imbruvica.
The new Opdivo approval covers patients with squamous non-small cell lung cancer no longer responsive to chemotherapy, according to an announcement made the FDA.
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
Obese Americans taking Contrave to lose weight cut their risk of having a heart attack, stroke or dying from heart disease by almost half compared to people taking a placebo.